FDA’s Pharmacy Compounding Advisory Committee is set to convene July 23–24 to consider whether seven peptides used for unproven indications should be added to products that can be compounded. The statement accompanying the news frames the review as a consequential step in tightening access to certain injectable peptides in the U.S. The commentary cites the HHS secretary’s characterization of an administration “war on peptides” and argues that expanding access without full approval could increase exposure to products previously viewed as too risky for compounding, potentially shifting incentives away from formal FDA drug development. The practical impact for biotech and pharma is that peptide manufacturers, contract compounding operations, and developers of peptide-based drugs could face more scrutiny on safety grounds, depending on how the advisory committee votes and what FDA does next. For the market, the key uncertainty is which specific peptides might be added or excluded. This development also signals that FDA’s enforcement posture may continue to shape how “grey-market” peptide supply channels evolve, with compliance guidance likely to become more important for downstream commercialization strategies.